A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days

Trial Profile

A Phase I, Randomized, Double-Blind, Parallel-Group, Study to Assess the Pharmacokinetics and Safety of Two Doses of PT010 and a Single Dose of PT003 in Healthy Chinese Adult Subjects Following A Single Administrations and After Chronic Administration for 7 Days

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2017

At a glance

  • Drugs Budesonide/formoterol/glycopyrrolate (Primary) ; Formoterol/glycopyrrolate (Primary)
  • Indications Chronic obstructive pulmonary disease
  • Focus Pharmacokinetics
  • Sponsors Pearl Therapeutics
  • Most Recent Events

    • 18 Aug 2017 Planned End Date changed from 1 Aug 2017 to 28 Sep 2017.
    • 18 Aug 2017 Planned primary completion date changed from 1 Aug 2017 to 28 Sep 2017.
    • 18 Aug 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top